Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Trainer

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Endocrinology and Metabolism|October 15, 2003
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithmDavid R Clemmons, Kazuo Chihara, Pamela U Freda, et al.
The Journal of Clinical Endocrinology and Metabolism|August 4, 2005
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomantAriel L Barkan, Pia Burman, David R Clemmons, et al.
European Journal of Endocrinology|January 9, 2016
Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegalyChristian J Strasburger, Niki Karavitaki, Sylvère Störmann, et al.
The Journal of Clinical Endocrinology and Metabolism|September 4, 2020
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral OctreotideSusan L Samson, Lisa B Nachtigall, Maria Fleseriu, et al.
European Journal of Endocrinology|May 24, 2018
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegalyPeter J Trainer, John D C Newell-Price, John Ayuk, et al.
European Journal of Endocrinology|July 1, 2011
The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristicsElena Valassi, Alicia Santos, Maria Yaneva, et al.
The Journal of Clinical Endocrinology and Metabolism|June 3, 2024
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral PaltusotineMônica R Gadelha, Alessandra Casagrande, Christian J Strasburger, et al.
Clinical Endocrinology|March 26, 2018
Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYNElena Valassi, Richard Feelders, Dominique Maiter, et al.
The Journal of Clinical Endocrinology and Metabolism|October 23, 2025
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-Daily Oral Paltusotine TreatmentBeverly M K Biller, Alessandra Casagrande, Atanaska Elenkova, et al.
European Journal of Endocrinology|September 4, 2019
High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registryElena Valassi, Antoine Tabarin, Thierry Brue, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Endocrinology and Metabolism|October 15, 2003
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithmDavid R Clemmons, Kazuo Chihara, Pamela U Freda, et al.
The Journal of Clinical Endocrinology and Metabolism|August 4, 2005
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomantAriel L Barkan, Pia Burman, David R Clemmons, et al.
European Journal of Endocrinology|January 9, 2016
Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegalyChristian J Strasburger, Niki Karavitaki, Sylvère Störmann, et al.
The Journal of Clinical Endocrinology and Metabolism|September 4, 2020
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral OctreotideSusan L Samson, Lisa B Nachtigall, Maria Fleseriu, et al.
European Journal of Endocrinology|May 24, 2018
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegalyPeter J Trainer, John D C Newell-Price, John Ayuk, et al.
European Journal of Endocrinology|July 1, 2011
The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristicsElena Valassi, Alicia Santos, Maria Yaneva, et al.
The Journal of Clinical Endocrinology and Metabolism|June 3, 2024
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral PaltusotineMônica R Gadelha, Alessandra Casagrande, Christian J Strasburger, et al.
Clinical Endocrinology|March 26, 2018
Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYNElena Valassi, Richard Feelders, Dominique Maiter, et al.
The Journal of Clinical Endocrinology and Metabolism|October 23, 2025
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-Daily Oral Paltusotine TreatmentBeverly M K Biller, Alessandra Casagrande, Atanaska Elenkova, et al.
European Journal of Endocrinology|September 4, 2019
High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registryElena Valassi, Antoine Tabarin, Thierry Brue, et al.
Pageof 6